 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
- | umbilical cord Wharton's jelly-derived human MSC - Public Assistance / Paris Hospitals
Trial completion, Trial primary completion date, Stroma: STROMA-CoV2: Cell Therapy Using Umbilical Cord-derived Mesenchymal Stromal Cells in SARS-CoV-2-related ARDS (clinicaltrials.gov) - Feb 18, 2022
P1/2, N=47, Completed, Sponsor: Assistance Publique - H
Active, not recruiting --> Completed | Trial primary completion date: Nov 2020 --> Oct 2021
- | umbilical cord Wharton's jelly-derived human MSC - Public Assistance / Paris Hospitals
Trial completion date, Stroma: STROMA-CoV2: Cell Therapy Using Umbilical Cord-derived Mesenchymal Stromal Cells in SARS-CoV-2-related ARDS (clinicaltrials.gov) - Sep 9, 2021
P1/2, N=47, Active, not recruiting, Sponsor: Assistance Publique - H
Active, not recruiting --> Completed | Trial primary completion date: Nov 2020 --> Oct 2021 Trial completion date: Apr 2022 --> Nov 2021
- | umbilical cord Wharton's jelly-derived human MSC - Public Assistance / Paris Hospitals
Enrollment closed, Trial primary completion date, Stroma: STROMA-CoV2: Cell Therapy Using Umbilical Cord-derived Mesenchymal Stromal Cells in SARS-CoV-2-related ARDS (clinicaltrials.gov) - Dec 3, 2020
P1/2, N=47, Active, not recruiting, Sponsor: Assistance Publique - H
Trial completion date: Apr 2022 --> Nov 2021 Recruiting --> Active, not recruiting | Trial primary completion date: Apr 2021 --> Jan 2021
- | umbilical cord Wharton's jelly-derived human MSC - Public Assistance / Paris Hospitals
Trial completion date, Trial primary completion date, Stroma: STROMA-CoV2: Cell Therapy Using Umbilical Cord-derived Mesenchymal Stromal Cells in SARS-CoV-2-related ARDS (clinicaltrials.gov) - Aug 17, 2020
P1/2, N=40, Recruiting, Sponsor: Assistance Publique - H
Recruiting --> Active, not recruiting | Trial primary completion date: Apr 2021 --> Jan 2021 Trial completion date: Jul 2021 --> Apr 2022 | Trial primary completion date: Aug 2020 --> Apr 2021
- | umbilical cord Wharton's jelly-derived human MSC - Public Assistance / Paris Hospitals
Enrollment change, Stroma: STROMA-CoV2: Cell Therapy Using Umbilical Cord-derived Mesenchymal Stromal Cells in SARS-CoV-2-related ARDS (clinicaltrials.gov) - May 21, 2020
P1/2, N=40, Recruiting, Sponsor: Assistance Publique - H
Trial completion date: Jul 2021 --> Apr 2022 | Trial primary completion date: Aug 2020 --> Apr 2021 N=60 --> 40
- | umbilical cord Wharton's jelly-derived human MSC - Public Assistance / Paris Hospitals
Enrollment open, Stroma: STROMA-CoV2: Cell Therapy Using Umbilical Cord-derived Mesenchymal Stromal Cells in SARS-CoV-2-related ARDS (clinicaltrials.gov) - Apr 27, 2020
P1/2, N=60, Recruiting, Sponsor: Assistance Publique - H
N=60 --> 40 Not yet recruiting --> Recruiting
- | umbilical cord Wharton's jelly-derived human MSC - Public Assistance / Paris Hospitals
New P1/2 trial, Stroma: STROMA-CoV2: Cell Therapy Using Umbilical Cord-derived Mesenchymal Stromal Cells in SARS-CoV-2-related ARDS (clinicaltrials.gov) - Apr 2, 2020
P1/2, N=60, Not yet recruiting, Sponsor: Assistance Publique - H